Year
Category
September 25, 2023
– Potential to address unmet need for millions of Canadian children and their parents with fast-acting, long-lasting liquid and chewable tablet – MONMOUTH JUNCTION, NJ, September 25, 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced…
September 05, 2023
– Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids – – Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023…
August 28, 2023
– Funding will support preclinical through Phase 2 studies, with preclinical research expected to initiate in Q4 2023 – MONMOUTH JUNCTION, NJ, August 28, 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced that…
May 02, 2023
– Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer – – Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas…
December 13, 2022
— Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids —…
Tris Pharma Announces Acquisition of New, Late-Stage Drug Candidate for Pain
December 07, 2022
Non-opioid, novel mechanism of action for pain, highly differentiated safety profile. Potential to address significant unmet needs in acute and chronic pain. MONMOUTH JUNCTION, NJ, December 7, 2022 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a fully integrated, innovation-driven CNS company with a robust portfolio of FDA-approved products for the…
December 01, 2022
MONMOUTH JUNCTION, NJ, December 1, 2022/ PRNewswire/ – Tris Pharma, Inc. (“Tris”),a fully integrated, innovation-driven CNS company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), and a pipeline of treatments for pain, addiction, spasticity and narcolepsy, and Pediatrix Therapeutics (“Pediatrix”), a pediatrics-focused company…
October 19, 2022
Once daily extended release provides early onset and full day coverage MONMOUTH JUNCTION, NJ, October 19, 2022 PRNewswire/ – Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII…
August 18, 2022
MONMOUTH JUNCTION, NJ, August 18, 2022/ PRNewswire/ – Tris Pharma, Inc. (“Tris”) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today the decision by the US District Court for the District of New Jersey to uphold the validity of various patents relating to QuilliChew ER®…
Tris Pharma Announces Availability of New DYANAVEL® XR (amphetamine) Tablets for ADHD
August 16, 2022
Once daily extended release provides early onset and full day coverage MONMOUTH JUNCTION, NJ, August 16, 2022/ PRNewswire/ – Tris Pharma, Inc. (Tris) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today that DYANAVEL® XR (amphetamine) extended-release tablets, for oral use, CII are now…
Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation
July 27, 2022
First oxybate product to provide both once a night dosing and very low sodium Novel formulation developed using Tris’s proprietary RaftWorksTM and LiquiXR® Technology MONMOUTH JUNCTION, July 27, 2022 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today…
July 22, 2022
Tris announces the publication of a Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of DYANAVEL XR Tablets in Adults with ADHD in the Journal of Clinical Psychiatry. The article can be found here. The study demonstrated that DYANAVEL XR tablets are an effective and well-tolerated treatment for the symptoms of ADHD in…
July 20, 2022
MONMOUTH JUNCTION, July 20, 2022 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision on July 7, 2022 upholding the validity and infringement of various…
November 05, 2021
In a clinical study in adults, DYANAVEL XR tablets demonstrated bioequivalence to DYANAVEL XR (amphetamine) extended-release oral suspension. ADHD patients taking Dyanavel XR oral suspension can conveniently switch to the same dose of DYANAVEL XR Tablets. With multiple dosage strengths, including one functionally-scored, DYANAVEL XR extended-release tablets offer several dosing…
October 07, 2021
MONMOUTH JUNCTION, NJ, October 7, 2021 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related conditions, today announced that Anthony Amato has joined…
April 29, 2021
Novel mechanism of action, highly differentiated safety profile, 2000+ subjects studied in 27 clinical trials across Europe and US; FDA Fast Track status granted NCE has potential to addresses significantly under-served market comprising acute and chronic pain, central and peripheral neuropathy, cancer pain, and addiction treatment MONMOUTH JUNCTION, NJ, April…
February 22, 2021
MONMOUTH JUNCTION, NJ and ATHENS, GA, February 22, 2021/ PRNewswire/ – Tris Pharma, Inc. (“Tris”) and Athena Bioscience LLC (“Athena”) announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using Tris’ proprietary technology. On average, only 50%…
APSARD and Tris Pharma Announce the 2021 Tris Research Award in ADHD
January 28, 2021
MONMOUTH JUNCTION, NJ, January 28, 2021 / PRNewswire/ – The American Professional Society of ADHD and Related Disorders (“APSARD”), a professional organization focused on improving outcomes for individuals with ADHD and their families, and Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products for…
January 20, 2021
Study met primary endpoint measure of sustained attention in adults with ADHD Showed statistically significant improvement vs. placebo in mean PERMP-Total score measured from 0.5 hours to 14 hours post-dose No new adverse reactions reported during the study MONMOUTH JUNCTION, NJ, January 20, 2021 / PRNewswire/ – Tris Pharma, Inc.
January 15, 2021
MONMOUTH JUNCTION, NJ, January 15, 2021 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that it will present pivotal…
Tris Pharma Hires Seasoned Research & Development Executive
December 18, 2020
Alfred Liang to join as Vice President, Research & Development MONMOUTH JUNCTION, NJ, December 18, 2020 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder…
December 08, 2020
MONMOUTH JUNCTION, NJ, DÜSSELDORF, GERMANY and BARCELONA, SPAIN, December 8, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company…
December 01, 2020
MONMOUTH JUNCTION, December 1, 2020 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, announced the decision by the US District Court for the District of Delaware to uphold…
November 17, 2020
MONMOUTH JUNCTION, NJ and PETACH TIKVA, ISRAEL, November 17, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and Medison Pharma (“Medison”), a leading international commercial partner for…
Tris Pharma Launches New ADHD Portfolio Website for Patients and Caregivers
November 10, 2020
MONMOUTH JUNCTION, NJ, November 10, 2020 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, today announced the launch of…
October 22, 2020
MONMOUTH JUNCTION, NJ, October 22, 2020 / PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, today announced that Amy Everitt, MS, PharmD…
Tris Pharma Launches its Scientific Advisory Board
October 06, 2020
MONMOUTH JUNCTION, NJ, October 6, 2020/PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, successfully convened the inaugural meeting of its Scientific…
Tris Pharma Launches Redesigned Website for ADHD Healthcare Professionals
September 17, 2020
MONMOUTH JUNCTION, NJ, September 17, 2020 / PRNewswire/ – Tris Pharma, Inc. (Tris), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, announced today the launch of a redesigned website for healthcare professionals (HCPs). This newly…
July 09, 2020
MONMOUTH JUNCTION, NJ and MISSISSAUGA, ONTARIO, CANADA, July 9, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of FDA-approved products for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, and KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga,…
Tris Pharma Launches New Corporate Website
June 25, 2020
MONMOUTH JUNCTION, NJ, June 25, 2020/ PRNewswire/ – Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, today announced the launch of a new…
March 17, 2020
MONMOUTH JUNCTION, NJ, March 17, 2020 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved...
APSARD and Tris Pharma Announce the Inaugural Tris Research Award in ADHD
January 17, 2020
MONMOUTH JUNCTION, NJ, January 17, 2020 / PRNewswire/ - The American Professional Society of ADHD and Related Disorders (APSARD) is a U.S.-based international...
Tris Pharma to Present Two Posters for Amphetamine Extended-Release Tablet at the 2019
November 07, 2019
MONMOUTH JUNCTION, NJ, November 7, 2019 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved...
Tris Pharma Adds Seasoned Attorney to its Senior Leadership Team
October 30, 2019
FOR IMMEDIATE RELEASE - MONMOUTH JUNCTION, NJ, October 30, 2019 / PRNewswire/ - Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust...
Tris Pharma Strengthens Its Branded Commercial Leadership Team
September 04, 2019
Todd Killian to lead Market Access and Trade Relations Scott Brunetto to lead Commercial Operations and Analytics MONMOUTH JUNCTION, NJ,...
August 14, 2019
FOR INFORMATION Cheryl Patnick (732) 823-4940 cpatnick@trispharma.com MONMOUTH JUNCTION, NJ, August 14, 2019 / PRNewswire/ - Tris Pharma,...
January 29, 2019
FOR IMMEDIATE RELEASE – January 29, 2019 – Monmouth Junction, NJ, Tris Pharma, Inc. is expanding the scope of its November 2018 recall by adding three (3)...
January 28, 2019
Tris Pharma recently issued an expansion of the voluntary recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL and an...
January 17, 2019
MONMOUTH JUNCTION, NJ, January 17, 2019 / PRNewswire/ - Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that...
December 06, 2018
Tris Pharma recently issued a voluntary recall and an associated press release regarding 3 batches (00717009A, 00717015A, 00717024A) of Infant’s Ibuprofen...
December 05, 2018
MONMOUTH JUNCTION, NJ, December 05, 2018 / PRNewswire/ -– Monmouth Junction, NJ, Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’...
November 12, 2018
The trial of children 6 to 12 years with ADHD demonstrated that DYANAVEL XR was effective in reducing symptoms of ADHD at 4 hours with a clinical onset at 1...
November 05, 2018
ENGLEWOOD, CO / ACCESSWIRE / November 5, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization...
October 25, 2018
MONMOUTH JUNCTION, NJ, October 24, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a biopharmaceutical company focused on developing innovative products that...
Tris Pharma Announces Hiring of Chief Commercial Officer
October 10, 2018
MONMOUTH JUNCTION, NJ, October 10, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative...
Deerfield Provides $125 million Debt Financing to Tris Pharma
October 04, 2018
Deerfield provides growth capital financing to Tris Pharma New York, New York – October 4, 2018 – Deerfield announced today it provided $125 million to...
Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals
September 25, 2018
MONMOUTH JUNCTION, NJ, September 25, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative...
Tris Pharma Announces Hiring of New Vice President of Quality & Compliance
August 27, 2018
MONMOUTH JUNCTION, NJ, August 27, 2018 / PRNewswire/ - Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative technology-based...
February 09, 2017
MONMOUTH JUNCTION, N.J., February 9, 2017 - Tris Pharma, Inc. (“Tris”) announced that results from a laboratory classroom study of DYANAVEL XR...
FDA accepts CCP-08 NDA for full review
December 20, 2016
Vernalis plc and Tris Pharma, Inc. (“Tris”) are pleased to announce that the U.S. Food and Drug Administration (“FDA”) has accepted the CCP-08 New...
FDA Accepts CCP-07 NDA for Full Review
September 05, 2016
Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-07 New Drug...
April 19, 2016
MONMOUTH JUNCTION, N.J., April 19, 2016 - Tris Pharma, Inc. ("Tris") announces today the launch of DYANAVEL™ XR (amphetamine), CII, the...
Tris Pharma Announces First Ever FDA-Approved Extended-Release Chewable Tablet
December 16, 2015
MONMOUTH JUNCTION, NJ, December 16, 2015 / PRNewswire/ - Tris Pharma, Inc. ("Tris") is pleased to announce that the U.S. Food and Drug Administration ("FDA")...
December 07, 2015
NEW YORK, N.Y., December 7 -- Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved QuilliChew ER chewable tablets. Pfizer...
October 20, 2015
MONMOUTH JUNCTION, N.J., October 20, 2015 -- Tris Pharma, Inc. ("Tris") announced that the U.S. Food and Drug Administration ("FDA") has approved...
Tris Pharma Launches Generic Tussionex® as Par’s Rights Expire
October 01, 2015
Monmouth Junction, N.J., Oct. 1, 2015 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery...
September 07, 2015
Vernalis plc (LSE: VER) and Tris Pharma today announce that Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex), extended-release oral...
August 13, 2015
CHARLOTTE, N.C., August 13, 2015; - FSC Pediatrics announced today the launch of Karbinal™ ER, the only 1st generation extended-release oral...
June 29, 2015
MONMOUTH JUNCTION, N.J., June 29, 2015; - Tris Pharma, Inc. ("Tris") today announced that it has entered into a license, supply, and distribution agreement...
Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel™ XR
May 21, 2015
MONMOUTH JUNCTION, N.J., May 21, 2015; - Tris Pharma, Inc. ("Tris") announced that U.S. Food and Drug Administration ("FDA") has accepted for review its...
Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR
May 01, 2015
MONMOUTH JUNCTION, N.J., May 1, 2015; - Vernalis plc and Tris Pharma Inc. today announce that the U.S. Food and Drug Administration (FDA) has approved the...
FDA accepts Tuzistra™ XR (CCP-01) NDA for full review
September 15, 2014
MONMOUTH JUNCTION, N.J., September 15, 2014; - Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug...
Tris Pharma Receives NJBIA Award for Excellence
August 27, 2014
MONMOUTH JUNCTION, N.J., August 27, 2014; - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,...
Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
July 22, 2014
Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-08, the third programme to achieve this milestone in their...
Submission of Tuzistra™ XR (CCP-01) NDA to FDA
June 30, 2014
Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that a New Drug Application ("NDA") has been submitted to the U.S. Food and Drug...
Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept
April 01, 2014
Vernalis plc and Tris Pharma, Inc. today announce the achievement of proof-of-concept (POC) for CCP-07, the second programme to achieve this milestone in...
February 01, 2014
Vernalis plc today announces successful completion of the second and final CCP-01 pivotal comparative bioavailability study. This positive multi-dose study...
September 04, 2013
MONMOUTH JUNCTION, N.J. & CHARLOTTE, N.C., September 4, 2013 -- Tris Pharma, Inc. and FSC Laboratories, Inc. today announced the signing of a definitive...
Tris Pharma’s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
July 10, 2013
MONMOUTH JUNCTION, N.J., July 10, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...
Tris Pharma Hires President for Generic Pharmaceuticals Business
June 20, 2013
MONMOUTH JUNCTION, N.J., June 20, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...
Tris Pharma’s Ketan Mehta Among Ernst & Young Entrepreneur Of The Year® 2013 Finalists in New Jersey
May 02, 2013
MONMOUTH JUNCTION, N.J., May 2, 2013 - Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...
April 03, 2013
MONMOUTH JUNCTION, N.J., April 3, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today...
March 11, 2013
MONMOUTH JUNCTION, N.J., March 11, 2013 -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies,...
January 14, 2013
NEW YORK, N.Y., January 14 - Pfizer Inc. (NYSE: PFE) today announced that Quillivant XR™ (methylphenidate hydrochloride) CII for extended-release oral...
Pfizer To Acquire NextWave Pharmaceuticals, Inc.
October 22, 2012
NEW YORK--(BUSINESS WIRE[1])--Pfizer Inc [2]. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals [3], a privately held, specialty...
Perrigo and Tris Pharma launch store brand version of Delsym®
August 27, 2012
ALLEGAN, Mich. and MONMOUTH JUNCTION, NJ – August 27, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) and Tris Pharma, Inc. today announced the commercial...
July 11, 2012
MONMOUTH JUNCTION, N.J., July 11; /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug...
May 31, 2012
MONMOUTH JUNCTION, N.J., May 31; /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company announced today that the US Food and Drug...
May 30, 2012
ALLEGAN, Mich. – May 30, 2012 – Perrigo Company (Nasdaq: PRGO;TASE) today announced that the U.S. Food and Drug Administration has granted final approval...
February 06, 2012
Vernalis plc (Vernalis), a UK development stage pharmaceutical company listed on the London Stock Exchange (LSE:VER) and Tris Pharma Inc (Tris) a privately...
Tris Pharma Announces US Patent Grant Covering Platform Technology
January 06, 2012
MONMOUTH JUNCTION, N.J., January 6; /PRNewswire/ -- Tris Pharma, an emerging specialty pharmaceutical company announced the US grant of its core technology...